Clinical trial
Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
NCT00176761 · University of Michigan Rogel Cancer Center, Other · Terminated
Key facts
| NCT number | NCT00176761 |
|---|---|
| Title | Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine |
| Official title | A Phase II Trial Assessing Autologous, Tumor-Pulsed Dendritic Cells as a Tumor Vaccine Administered With IL-2 in Patients With Metastatic Colorectal Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | University of Michigan |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Colorectal Cancer |
| Intervention type | Drug |
| Interventions | Interleukin-2 (IL-2) |
| Enrollment | 27 |
| Start date | Mar 1, 2000 |
| Completion | May 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | Sep 11, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: